The current combination of ICI therapies and anti-CD73 antibodies are attractive therapeutic approaches, and are under evaluation [40] with the aim to improve the outcome in patients with NSCLC that did not response to ICI (monotherapy or combination with chemotherapy). This evidence concerns the gene NT5E and non-small cell lung carcinoma.